What’s Going On With Concentrix Stock After The Close?

Concentrix Corp (NASDAQ: CNXC) shares are trading lower in Wednesday's after-hours session after the customer experience solutions company reported mixed quarterly results and announced a business combination with Webhelp.

Concentrix Corp (NASDAQ:CNXC) shares are trading lower in Wednesday’s after-hours session after the customer experience solutions company reported mixed quarterly results and announced a business combination with Webhelp.

  • Q1 Revenue: $1.64 billion beat estimates of $1.63 billion
  • Q1 EPS: $2.56 missed estimates of $2.59

Concentrix anticipates second-quarter revenue growth in the range of 3% to 5%. Operating income is expected to be between $167 million and $177 million.

Concentrix also entered into an agreement to combine with Webhelp in a transaction valued at $4.8 billion. The combined company is expected to have approximately $9.8 billion in estimated pro forma 2023 revenue. Concentrix said it would be uniquely positioned to grow faster than the market.

“As we embark on this new journey together, we will have the most impressive toolkit of high-value services and digital capabilities, and a complementary portfolio of approximately 2,000 amazing clients with a diversified and robust revenue stream,” said Chris Caldwell, president and CEO of Concentrix.

See Also: Sprinklr Shares Surge On Strong Q4 Results: The Details

CNXC Price Action: Concentrix shares were down 7.24% after hours at $112.95 at the time of publication, according to Benzinga Pro.

Photo: StartupStockPhotos from Pixabay.

Total
0
Shares
Related Posts
Read More

Renovaro Biosciences And AI Health Company GEDi Cube Sign Definitive Agreement To Combine; GEDi Cube To Become A Wholly-Owned Subsidiary Of Renovaro In Stock-For-Stock Acquisition; GEDi Cube Holders To Own ~50% Of Combined Company

The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug

RENB